Engineering of the hematopoietic graft is an attractive approach to improving outcomes for patients undergoing hematopoietic cell transplantation. In this issue’s Blood Advances Talk, Marie Bleakley describes her group’s efforts in depletion of naïve T cells to reduce graft-versus-host disease and maintain graft-versus-tumor reactions. We hope you find this talk useful and informative.
Successful transfer of anti–SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19
The use of convalescent plasma for the treatment of patients with COVID-19 continues to of great interest and recent clinical application. In an Exceptional Case Report, Luetkens and colleagues describe a patient with multiple myeloma and hypogammaglobulinemia who developed severe COVID-19 and was successfully treated with convalescent plasms, highlighting the potential effectiveness of this therapeutic.
Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews
In hospitalized medical patients, the risk of venous thromboembolism (VTE) must be counter balanced by the risk of bleeding when considering anticoagulation strategies. In a Systematic Review, Darzi and colleagues evaluate risk assessment models which informed the formation of the American Society of Hematology’s Clinical Guidelines addressing VTE.
Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients
Blastic plasmacytoid dendritic cell neoplasms (BPDCNs) are rare but carry a dismal prognosis. In an international survey of 398 adult patients, Laribi and colleagues evaluated various treatment strategies with important clinical conclusions that could help standardize therapy and lead to future improvements in outcomes of this devastating disease.
Ferroportin is known as perhaps the sole iron exporter in humans. However, the molecular mechanisms involved are incompletely understood. Li and colleagues explored targeted mutagenesis of ferroportin to gain further insight into the molecular mechanisms of action of this important iron transporter.
Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE)
Treatment of children with catheter-related thrombosis has not been specifically addressed in a comprehensive way. Thom and colleagues, on behalf of the EINSTEIN-Jr. CVC-VTE investigators, evaluated 500 children to provide important clinical observations on the treatment of this patient population.